CG Oncology, Inc. · NASDAQ:CGON
CG Oncology — Investor Presentation (June 2024)
28 slides from CG Oncology's investor presentation, June 2024
Slide 1: Attacking Bladder Cancer for a Better Tomorrow
Attacking Bladder Cancer for a Better Tomorrow | 1
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and
Slide 3: Investment Summary
Investment Summary ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪
Slide 4: Comprehensive Programs in High-Risk and Intermediate-Risk NMIBC
Comprehensive Programs in High-Risk and Intermediate-Risk NMIBC Addressing a Multi-Billion Dollar Market Opportunity COMPOUND/INDICATION PHASE 1 PHASE 2 PHASE 3 ANTICIPATED MILESTONES BOND-003 Cohort C BCG-Unresponsive, High-Risk NMIBC (BOND-003) pivotal data in 2H’24 CORE-001 24-month BCG-Unrespons
Slide 5: Executive Leadership Team
Executive Leadership Team | 5
Slide 6: Attacking Bladder Cancer for a Better Tomorrow
Attacking Bladder Cancer for a Better Tomorrow
Slide 7: Bladder Cancer is a Significant Unmet Medical Need
Bladder Cancer is a Significant Unmet Medical Need Well Positioned for Innovation and Disruption | 7
Slide 8: NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer
NMIBC Represents a Multi-Billion insice othe Bladder wall Outside of the bladder wall bladder wall Dollar Market Opportunity in i Bladder Cancer Nonttusdeinmnive fl cis fl Bladder Cancer NMIBC Carcinoma in Situ (CIS) Non-Invasive Papillary Carcinoma Ta Tumor Invades Connective Tissue ~75% of Newly D
Slide 9: Current NMIBC treatment paradigm
(1) Symptom Ongoing Treatment Require surveillance and/or Patient presents to primary care treatment every 3 to 6 months and/or urologist with symptoms for 2 to 5 years (hematuria, urinary frequency) Testing Work-up may include cystoscopy, urine cytology, + Low-Risk and imaging (CT scan, MRI) Periop
Slide 10: FDA Guidance on BCG-Unresponsive NMIBC De-Risks Development & Regulatory Pathway to BLA Approval
FDA Guidance on BCG-Unresponsive NMIBC De-Risks Development & Regulatory Pathway to BLA Approval Single-arm trials with complete response rate as primary endpoint in the context of duration of response may be appropriate for a full approval. BCG-unresponsive disease defined as either: • Persistent o
Slide 11: 1b 1a Creto
1 2 1a 1b T-Cell Creto Tumor Progeny Antigens GM-CSF Cancer Cell
Slide 12: Cretostimogene Selectively Targets Rb-E2F Pathway Defective Cancers
Cretostimogene Selectively Targets Rb-E2F Pathway Defective Cancers Cretostimogene grenadenorepvec Cretostimogene grenadenorepvec in Normal Cells in Tumor Cells o o | 12
Slide 13: Cretostimogene is Intravesically Administered into the Bladder
Cretostimogene is Intravesically Administered into the Bladder, Similar to Standard-of-Care BCG Therapy Which Urology Practices Perform Regularly GAG Layer Tumor Standard Catheter Cretostimogene β | 13
Slide 14: Ease of Delivery and Administration for Patients, Physicians, and Practice Providers
Ease of Delivery and Administration for Patients, Physicians, and Practice Providers
Slide 15: Our Goal is to Establish Cretostimogene as Backbone Therapy for NMIBC
Our Goal is to Establish Cretostimogene as Backbone Therapy for High-Risk and Intermediate-Risk NMIBC Patients
Slide 16: Phase 3 Cretostimogene Monotherapy for BCG-Unresponsive, High-Risk NMIBC (NCT04452591)
Phase 3 Cretostimogene Monotherapy for BCG-Unresponsive, High-Risk NMIBC (NCT04452591) ▪ ▪ ▪ o o o ▪ o o o ▪ ▪ ▪ ▪ o o o
Slide 17: Patient Demographics & Baseline Characteristics
Patient Demographics & Baseline Characteristics ▪ Gender o o Age (Years) o ▪ Age (Categories) o BCG History: Number of Prior Instillations High-Risk NMIBC T-Stage at Study Entry
Slide 18: Cretostimogene Monotherapy Results in Cohort C: Largest Dataset in BCG-Unresponsive, High-Risk NMIBC
Cretostimogene Monotherapy Results in Cohort C: Largest Dataset in BCG-Unresponsive, High-Risk NMIBC ▪ ▪ ▪
Slide 19: AUA 2024: Updated Results from BOND-003 Cohort C
AUA 2024: Updated Results from BOND-003 Cohort C Cretostimogene Monotherapy for BCG-Unresponsive, High-Risk NMIBC ▪ ▪ ▪
Slide 20: Cretostimogene Has Been Generally Well-Tolerated
Cretostimogene Has Been Generally Well-Tolerated ▪ ▪ ▪ ▪ ▪
Slide 21: Phase 2 Cretostimogene + Pembrolizumab for BCG-Unresponsive, High-Risk NMIBC CIS (NCT04387461)
Phase 2 Cretostimogene + Pembrolizumab for BCG-Unresponsive, High-Risk NMIBC CIS (NCT04387461) CR at 12-months ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ 3 All patients required to undergo mandatory, systematic bladder mapping of 5 locations, biopsy of the prostatic urethra, and upper tract imaging to confirm CR.
Slide 22: Cretostimogene Combo with Pembrolizumab: Potential Class-Leading Response
Cretostimogene Combo with Pembrolizumab: Potential Class-Leading Response ▪ ▪ ▪ ▪ o
Slide 23: ASCO 2024: Updated Long-Term Durability Data
ASCO 2024: Updated Long-Term Durability Data Cretostimogene + Pembrolizumab Combo for BCG-Unresponsive, High-Risk NMIBC
Slide 24: Favorable Safety Profile with No Overlapping or Synergistic Toxicity in Combination
Favorable Safety Profile with No Overlapping or Synergistic Toxicity in Combination of Cretostimogene and Pembrolizumab ▪ ▪ ▪ ▪ ▪
Slide 25: Pioneering Class-Leading Oncolytic Immunotherapy with Differentiated Clinical Profile
Pioneering Class-Leading Oncolytic Immunotherapy with Differentiated Clinical Profile Against Approved and Investigational NMIBC Agents1 Trial BOND-003 CORE-001 QUILT 3.032 NCT02773849 KEYNOTE-057 SunRISe-1 LEGEND Intervention Mechanism RoA Stage Sample Size CR at Any Time CR at 12 Mo CR at 24 Mo Do
Slide 26: Phase 3 Adjuvant Cretostimogene Following TURBT Versus Surveillance for Intermediate-Risk NMIBC
Phase 3 Adjuvant Cretostimogene Following TURBT Versus Surveillance Following TURBT for Intermediate-Risk NMIBC RFS Rate ▪ ▪ ▪ o o o ▪ o o ▪ ▪ o o o ▪
Slide 27: CG Oncology Highlights
CG Oncology Highlights 1 2 3 4 5
Slide 28: CG Oncology Inc. Contact
CG Oncology Inc. Information@cgoncology.com 400 Spectrum Center Dr Suite #2040 Irvine, CA 92618 MediaRelations@cgoncology.com | 28